Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase

This article was originally published in The Tan Sheet

Executive Summary

While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline

You may also be interested in...



Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market

Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.

Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market

Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.

GSK Looks To Expand OTC Reach With CNS Brands

GlaxoSmithKline will pay nearly five times CNS's 12-month sales total to widen its consumer reach with the acquisition of CNS, the Minneapolis-based maker of Breathe Right and FiberChoice products

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel